Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre, open label, phase 2, randomised controlled trial of patients with
advanced triple negative breast cancer (TNBC) who have received no more than one line of
chemotherapy (not including neoadjuvant or adjuvant therapy) who will be randomised to be
treated with SABR 20Gy in 1# followed by atezolizumab or SABR 24Gy in 3# followed by
atezolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Collaborators:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)